Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC

Nanruoyi Zhou, Maria A. Velez, Benjamin Bachrach, Jaklin Gukasyan, Charlene M. Fares, Amy L. Cummings, Jackson P Lind-Lebuffe, Wisdom O. Akingbemi, Debory Li, Paige M Brodrick, Nawal M Yessuf, Sarah Rettinger, Tristan Grogan, Philippe Rochigneux, Jonathan W. Goldman, Edward B. Garon, Aaron Lisberg